💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Lawsuits Against Pfizer's Lipitor Spike In Past 5 Months

Published 08/08/2014, 08:16 AM
Updated 08/08/2014, 08:45 AM
Lawsuits Against Pfizer's Lipitor Spike In Past 5 Months
PFE
-

By Sneha Shankar - New-York-based pharmaceutical giant Pfizer Inc. NYSE:PFE saw a steep hike in the number of lawsuits filed against it by American women claiming that the company knew about the side-effects of its blockbuster cholesterol drug Lipitor but did not issue an official warning.

The number of federal court filings against the company has reportedly increased from 56 to 1,000 in the last five months, where plaintiffs claim that the use of Lipitor for lowering cholesterol levels, gave them type-2 diabetes. The recent spike in lawsuits against the company follows an order from a federal judicial panel to bring all the cases filed across the U.S. against Pfizer into a single courtroom. Pfizer, which plans to contest the claims, has reportedly declined to follow the order claiming it will trigger copycat lawsuits.

"We will ask a jury to decide what it's worth to take five years of someone's life," H. Blair Hahn, of Mount Pleasant, South Carolina, and the plaintiffs' lead lawyer said, according to Reuters. Hahn also said that the 1,000 cases filed so far represent nearly 4,000 women, and estimated that the number of cases could rise ten-fold to 10,000.

Lipitor belongs to a class of drugs called statins, which work in the liver to reduce the production of cholesterol, while diabetes takes away the body's ability to produce insulin, which helps convert food to energy.

In 2012, the U.S. Food and Drug Administration, or FDA, reportedly issued a warning that the use of statin drugs like Lipitor could increase the risk of diabetes and memory loss. In January, the FDA warning was updated to provide a detailed list of side effects, including muscle damage and liver injury in extreme cases.

© Reuters/Andrew Kelly. The Pfizer logo is seen at their world headquarters in New York on April 28, 2014.

“Clearly we think that the heart benefit of statins outweighs this small increased risk,” Amy G. Egan, deputy director for safety in FDA’s Division of Metabolism and Endocrinology Products, said in the FDA statement, adding that the patients might have to be tested for their blood-sugar levels regularly, after they begin treatment with statins.

A recent report by the World Health Organization stated that heart disease was the leading cause of deaths in 2011 and 2012 while one out of three children have high cholesterol.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.